Review of available drugs and non-pharmacological strategies used to treat insomnia
DOI:
https://doi.org/10.56782/pps.228Keywords:
insomnia, CBT-I, hypnotics, melatonin, non-BZRAAbstract
Insomnia is one of the most prevalent sleep disorders occurring worldwide among the adult population. Prolonged lack of proper nightly rest can have a significant impact not only on the psychological individual well-being but also on their overall somatic health. Due to said problem’s frequent occurrence it is important that every clinician has a basic knowledge of available treatment options for insomnia. Currently, both pharmacological options as well as non-pharmacological approaches can be implemented to improve sleep quality. When choosing a specific treatment method, one must consider the patient's health factors such as comorbidities, age, chronically used medications, and financial resources. Nowadays the first recommended line of treating insomnia is focused on cognitive behavioral therapy (CBT), behavioral changes, and patient education in matters of sleep hygiene. In certain cases, it may be beneficial to implement hypnotic drugs, of which non-benzodiazepine benzodiazepine receptor agonists (non-BZRA) have relatively highest numbers of studies dedicated to testing their efficacy and safety. In patients with coexisting psychiatric disorders, certain antidepressants may play a significant role in sleep disorders management. Despite the prevalence of sleep disorders in the general population there still exists a need to conduct more comprehensive studies directly comparing distinct groups of hypnotic drugs – both their safety profile as well as their efficacy in treating insomnia.
Downloads
References
1. Pavlova, M.; Latreille, V. Sleep Disorders. Am. J. Med. 2018, 132(3), 292-299. DOI: 10.1016/j.amjmed.2018.09.021 DOI: https://doi.org/10.1016/j.amjmed.2018.09.021
2. Roth, T. Insomnia: definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 2007, 3(Suppl), S7–S10. DOI: https://doi.org/10.5664/jcsm.26929
3. Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health [Internet]. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016 Jun. Table 3.36, DSM-IV to DSM-5 Insomnia Disorder Comparison. Available online: https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t36/ (accessed on 29 May 2024)
4. Ohayon, M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev. 2002, 6, 97–111. DOI: 10.1053/smrv.2002.0186 DOI: https://doi.org/10.1053/smrv.2002.0186
5. Hirshkowitz, M.; Whiton, K.; Albert, S.M.; Alessi, C.; Bruni, O.; DonCarlos, L.; Hazen, N.; Herman, J.; Katz, E.S.; Kheirandish-Gozal, L.; Neubauer, D.N.; O'Donnell, A.E.; Ohayon, M.; Peever, J.; Rawding, R.; Sachdeva, R.C.; Setters, B.; Vitiello, M.V.; Ware, J.C.; Adams Hillard, P.J. National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep Health 2015, 1, 40–43. DOI: 10.1016/j.sleh.2014.12.010 DOI: https://doi.org/10.1016/j.sleh.2014.12.010
6. Passarella, S.; Duong, M.-T. Diagnosis and treatment of insomnia. Am. J. Health-Syst. Pharm. 2008, 65, 927–934. DOI: 10.2146/ajhp060640 DOI: https://doi.org/10.2146/ajhp060640
7. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed.; American Academy of Sleep Medicine: Darien, IL, 2014
8. Sateia, M.J.; Buysse, D.J.; Krystal, A.D.; Neubauer, D.N.; Heald, J.L. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J. Clin. Sleep Med. 2017, 13, 307–349. DOI: 10.5664/jcsm.6470 DOI: https://doi.org/10.5664/jcsm.6470
9. Bounds, C.G.; Patel, P.; Nelson, V.L. Benzodiazepines. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; Updated 2024 Jan 30. Available online: https://www.ncbi.nlm.nih.gov/books/NBK470159/ (accessed on 29 May 2024)
10. Riemann, D.; Espie, C.A.; Altena, E.; Arnardottir, E.S.; Baglioni, C.; Bassetti, C.L.A.; Bastien, C.; Berzina, N.; Bjorvatn, B.; Dikeos, D.; Dolenc Groselj, L.; Ellis, J.G.; Garcia-Borreguero, D.; Geoffroy, P.A.; Gjerstad, M.; Gonçalves, M.; Hertenstein, E.; Hoedlmoser, K.; Hion, T.; …; Spiegelhalder, K. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J. Sleep Res. 2023, 32, Art. No: e14035. DOI: 10.1111/jsr.14035 DOI: https://doi.org/10.1111/jsr.14035
11. Holbrook, A.M.; Crowther, R.; Lotter, A.; Cheng, C.; King, D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000, 162, 225–233.
12. Asnis, G.M.; Thomas, M.; Henderson, M.A. Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int. J. Mol. Sci. 2015, 17, Art. No: 50. DOI: 10.3390/ijms17010050 DOI: https://doi.org/10.3390/ijms17010050
13. Neubauer, D.N.; Benca, R.; Elmore, J.G. Pharmacotherapy for insomnia in adults. In: UpToDate, Connor, R.F. (Ed.); Wolters Kluwer. Available from: https://sso.uptodate.com/contents/pharmacotherapy-for-insomnia-in-adults (Accessed on 9 May 2024)
14. Huedo-Medina, T.B.; Kirsch, I.; Middlemass, J.; Klonizakis, M.; Siriwardena, A.N. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012, 345, Art. No: e8343. DOI: 10.1136/bmj.e8343 DOI: https://doi.org/10.1136/bmj.e8343
15. De Crescenzo, F.; D'Alò, G.L.; Ostinelli, E.G.; Ciabattini, M.; Di Franco, V.; Watanabe, N.; Kurtulmus, A.; Tomlinson, A.; Mitrova, Z.; Foti, F.; Del Giovane, C.; Quested, D.J.; Cowen, P.J.; Barbui, C.; Amato, L.; Efthimiou, O.; Cipriani, A. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 2022, 400(10347), 170-184. DOI: 10.1016/S0140-6736(22)00878-9 DOI: https://doi.org/10.1016/S0140-6736(22)00878-9
16. Najib, J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin. Ther. 2006, 28, 491–516. DOI: 10.1016/j.clinthera.2006.04.014 DOI: https://doi.org/10.1016/j.clinthera.2006.04.014
17. Wagner, J.; Wagner, M.L. Non-benzodiazepines for the treatment of insomnia. Sleep Med. Rev. 2000, 4, 551–581. DOI: 10.1053/smrv.2000.0126 DOI: https://doi.org/10.1053/smrv.2000.0126
18. Zolpidem and Hallucinations. Ann. Emerg. Med. 1997, 29, 300–301. DOI: 10.1016/s0196-0644(97)70291-9 DOI: https://doi.org/10.1016/S0196-0644(97)70291-9
19. Brott, N.R.; Reddivari, A.K.R. Doxylamine. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; Updated 2023 Jun 5. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551646/ (accessed on 29 May 2024)
20. Schadeck, B.; Chelly, M.; Ansellem, D.; Cohen, A.; Peraudeau, P.; et al. Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) for the treatment of common insomnia: a placebo-controlled study. La Semaine Hôpitaux Paris 1996, 72, 428–439.
21. Sicari, V.; Zabbo, C.P. Diphenhydramine. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; Updated 2023 Jul 10. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526010/ (accessed on 29 May 2024)
22. Morin, C.M.; Koetter, U.; Bastien, C.; Ware, J.C.; Wooten, V. Valerian–hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005, 28, 1465–1471. DOI: 10.1093/sleep/28.11.1465 DOI: https://doi.org/10.1093/sleep/28.11.1465
23. Llorca, P.M.; Spadone, C.; Sol, O.; Danniau, A.; Bougerol, T.; Corruble, E.; Faruch, M.; Macher, J.P.; Sermet, E.; Servant, D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J. Clin. Psychiatry 2002, 63, 1020–1027. DOI: 10.4088/jcp.v63n1112 DOI: https://doi.org/10.4088/JCP.v63n1112
24. Burgazli, C.R.; Rana, K.B.; Brown, J.N.; Tillman, F. 3rd. Efficacy and safety of hydroxyzine for sleep in adults: systematic review. Hum. Psychopharmacol. 2023, 38, Art. No: e2864. DOI: 10.1002/hup.2864 DOI: https://doi.org/10.1002/hup.2864
25. Li, L.; Liu, R.; Peng, C.; Chen, X.; Li, J. Pharmacogenomics for the efficacy and side effects of antihistamines. Exp. Dermatol. 2022, 31, 993–1004. DOI: 10.1111/exd.14602 DOI: https://doi.org/10.1111/exd.14602
26. Abad, V.C.; Guilleminault, C. Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging 2018, 35, 791–817. DOI: 10.1007/s40266-018-0569-8 DOI: https://doi.org/10.1007/s40266-018-0569-8
27. Krzystanek, M.; Krysta, K.; Pałasz, A. First generation antihistaminic drugs used in the treatment of insomnia – superstitions and evidence. Pharmacol. Psychiat. Neurol. (Farmakoterapia w Psychiatrii i Neurologii) 2020, 36, 33–40. DOI: https://doi.org/10.33450/fpn.2020.04.003
28. Alston, M.; Cain, S.W.; Rajaratnam, S.M.W. Advances of melatonin-based therapies in the treatment of disturbed sleep and mood. Handb. Exp. Pharmacol. 2019, 253, 305–319. DOI: 10.1007/164_2018_139 DOI: https://doi.org/10.1007/164_2018_139
29. Del Rio Verduzco, A.; Salari, A.; Haghparast, P. Efficacy and safety of pharmacotherapy in chronic insomnia: a review of clinical guidelines and case reports. Ment. Health Clin. 2023, 13, 244–254. DOI: 10.9740/mhc.2023.10.244 DOI: https://doi.org/10.9740/mhc.2023.10.244
30. Wade, A.G.; Ford, I.; Crawford, G.; McConnachie, A.; Nir, T.; Laudon, M.; Zisapel, N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo-controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010, 8, Art. No: 51. DOI: 10.1186/1741-7015-8-51 DOI: https://doi.org/10.1186/1741-7015-8-51
31. Wei, S.; Smits, M.G.; Tang, X.; Kuang, L.; Meng, H.; Ni, S.; Xiao, M.; Zhou, X. Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials. Sleep Med. 2020, 68, 1–8. DOI: 10.1016/j.sleep.2019.02.017 DOI: https://doi.org/10.1016/j.sleep.2019.02.017
32. van Geijlswijk, I.M.; Korzilius, H.P.; Smits, M.G. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010, 33, 1605–1614. DOI: 10.1093/sleep/33.12.1605 DOI: https://doi.org/10.1093/sleep/33.12.1605
33. Gringras, P.; Nir, T.; Breddy, J.; Frydman-Marom, A.; Findling, R.L. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J. Am. Acad. Child Adolesc. Psychiatry 2017, 56, 948–957.e4. DOI: 10.1016/j.jaac.2017.09.414 DOI: https://doi.org/10.1016/j.jaac.2017.09.414
34. Riemann, D.; Espie, C.A.; Altena, E.; Arnardottir, E.S.; Baglioni, C.; Bassetti, C.L.A.; Bastien, C.; Berzina, N.; Bjorvatn, B.; Dikeos, D.; Dolenc Groselj, L.; Ellis, J.G.; Garcia-Borreguero, D.; Geoffroy, P.A.; Gjerstad, M.; Gonçalves, M.; Hertenstein, E.; Hoedlmoser, K.; Hion, T.; Holzinger, B.; Janku, K.; Jansson-Fröjmark, M.; Järnefelt, H.; Jernelöv, S.; Jennum, P.J.; Khachatryan, S.; Krone, L.; Kyle, S.D.; Lancee, J.; Leger, D.; Lupusor, A.; Marques, D.R.; Nissen, C.; Palagini, L.; Paunio, T.; Perogamvros, L.; Pevernagie, D.; Schabus, M.; Shochat, T.; Szentkiralyi, A.; Van Someren, E.; van Straten, A.; Wichniak, A.; Verbraecken, J.; Spiegelhalder, K. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J. Sleep Res. 2023, 32, Art. No: e14035. DOI: 10.1111/jsr.14035 DOI: https://doi.org/10.1111/jsr.14035
35. Matheson, E.; Hainer, B.L. Insomnia: pharmacologic therapy. Am. Fam. Physician 2017, 96, 29–35.
36. McCall, C.; McCall, W.V. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Curr. Psychiatry Rep. 2012, 14, 494–502. DOI: 10.1007/s11920-012-0302-y DOI: https://doi.org/10.1007/s11920-012-0302-y
37. Skalski, M. Jakie leki należy stosować w leczeniu bezsenności? Medycyna Po Dyplomie 2019, 05. Available online: https://podyplomie.pl/medycyna/32578,jakie-leki-nalezy-stosowac-w-leczeniu-bezsennosci (accessed on 29 May 2024)
38. Shin, J.J.; Saadabadi, A. Trazodone. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024 Feb 29. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470560/ (accessed on 29 May 2024)
39. Wichniak, A.; Wierzbicka, A.; Wałęcka, M.; Jernajczyk, W. Effects of antidepressants on sleep. Curr. Psychiatry Rep. 2017, 19, Art. No: 63. DOI: 10.1007/s11920-017-0816-4 DOI: https://doi.org/10.1007/s11920-017-0816-4
40. Nierenberg, A.A.; Adler, L.A.; Peselow, E.; Zornberg, G.; Rosenthal, M. Trazodone for antidepressant-associated insomnia. Am. J. Psychiatry 1994, 151, 1069–1072. DOI: https://doi.org/10.1176/ajp.151.7.1069
41. Kaynak, H.; Kaynak, D.; Gözükmizi, E.; Guilleminault, C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004, 5, 15–20. DOI: https://doi.org/10.1016/j.sleep.2003.06.006
42. Hertzberg, M.A.; Feldman, M.E.; Beckham, J.C.; Davidson, J.R.T. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J. Clin. Psychopharmacol. 1996, 16, 294–298. DOI: https://doi.org/10.1097/00004714-199608000-00004
43. Roth, A.J.; McCall, W.V.; Liguori, A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J. Sleep Res. 2011, 20, 552–558. DOI: 10.1111/j.1365-2869.2011.00928.x DOI: https://doi.org/10.1111/j.1365-2869.2011.00928.x
44. Montgomery, I.; Oswald, I.; Morgan, K.; Adam, K. Trazodone enhances sleep in subjective quality but not in objective duration. Br. J. Clin. Pharmacol. 1983, 16, 139–144. DOI: 10.1111/j.1365-2125.1983.tb04977.x DOI: https://doi.org/10.1111/j.1365-2125.1983.tb04977.x
45. Yi, X.-y.; Ni, S.-f.; Ghadami, M.R.; Meng, H.-q.; Chen, M.-y.; Kuang, L.; Zhang, Y.-q.; Zhang, L.; Zhou, X.-y. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2018, 45, 25–32. DOI: 10.1016/j.sleep.2018.01.010 DOI: https://doi.org/10.1016/j.sleep.2018.01.010
46. Jilani, T.N.; Gibbons, J.R.; Faizy, R.M.; Saadabadi, A. Mirtazapine. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Aug 28. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519059/ (accessed on 29 May 2024)
47. Schmid, D.A.; Wichniak, A.; Uhr, M.; Ising, M.; Brunner, H.; Held, K.; Weikel, J.C.; Sonntag, A.; Steiger, A. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX–CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacol. 2006, 31, 832–844. DOI: 10.1038/sj.npp.1300923 DOI: https://doi.org/10.1038/sj.npp.1300923
48. Aslan, S.; Isik, E.; Cosar, B. The effects of mirtazapine on sleep: a placebo-controlled, double-blind study in young healthy volunteers. Sleep 2002, 25, 677–679. DOI: https://doi.org/10.1093/sleep/25.6.666
49. Perez, D.; Loprinzi, D.; Barton, D.L. Pilot evaluation of mirtazapine for the treatment of hot flashes. J. Support. Oncol. 2004, 2, 50–56
50. Wingen, M.; Bothmer, J.; Langer, S.; Ramaekers, J.G. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J. Clin. Psychiatry 2005, 66, 436–443. DOI: 10.4088/jcp.v66n0405 DOI: https://doi.org/10.4088/JCP.v66n0405
51. Sobańska, A.; Wichniak, A.; Wierbicka, A.; Szatkowska, E.; Czasak, K.; Musińska, I.; Jernajczyk, W. Mianserin for primary insomnia treatment. Sen 2006, 6, 58–63
52. Ramaekers, J.G.; Swijgman, H.F.; O'Hanlon, J.F. Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacol. (Berl.) 1992, 106 (Suppl), S62–S67. DOI: 10.1007/BF02246238 DOI: https://doi.org/10.1007/BF02246238
53. Weber, J.; Siddiqui, M.A.; Wagstaff, A.J.; McCormack, P.L. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010, 24, 713–720. DOI: 10.2165/11200810-000000000-00000 DOI: https://doi.org/10.2165/11200810-000000000-00000
54. Roth, T.; Rogowski, R.; Hull, S.; Schwartz, H.; Koshorek, G.; Corser, B.; Seiden, D.; Lankford, A. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007, 30, 1555–1561. DOI: 10.1093/sleep/30.11.1555 DOI: https://doi.org/10.1093/sleep/30.11.1555
55. Krystal, A.D.; Lankford, A.; Durrence, H.H.; Ludington, E.; Jochelson, P.; Rogowski, R.; Roth, T. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011, 34, 1433–1442. DOI: 10.5665/SLEEP.1294 DOI: https://doi.org/10.5665/SLEEP.1294
56. Leach, M.J.; Page, A.T. Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med. Rev. 2015, 24, 1–12. DOI: 10.1016/j.smrv.2014.12.003 DOI: https://doi.org/10.1016/j.smrv.2014.12.003
57. Khadivzadeh, T.; Abdolahian, S.; Ghazanfarpour, M.; Kargarfard, L.; Dizavandi, F.R.; Khorsand, I. A systematic review and meta-analysis on the effect of herbal medicine to manage sleep dysfunction in peri- and postmenopause. J. Menopaus. Med. 2018, 24, 92–99. DOI: 10.6118/jmm.2018.24.2.92 DOI: https://doi.org/10.6118/jmm.2018.24.2.92
58. Baek, J.H.; Nierenberg, A.A.; Kinrys, G. Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. Aust. N. Z. J. Psychiatry 2014, 48, 705–715. DOI: 10.1177/0004867414539198; PMID: 24947278 DOI: https://doi.org/10.1177/0004867414539198
59. Borrás, S.; Martínez-Solís, I.; Ríos, J.L. Medicinal plants for insomnia related to anxiety: an updated review. Planta Med. 2021, 87, 738–753. DOI: 10.1055/a-1510-9826 DOI: https://doi.org/10.1055/a-1510-9826
60. Feizi, F.; Namazi, N.; Rahimi, R.; Ayati, M.H. Medicinal plants for management of insomnia: a systematic review of animal and human studies. Galen Med. J. 2019, 8, Art. No: e1085. DOI: 10.31661/gmj.v8i0.1085 DOI: https://doi.org/10.31661/gmj.v8i0.1085
61. Chun, W.; Chao, D.; Qi, H.; Dongliang, Z.; Zhenmei, L.; Jia, L. Pharmacological and non-pharmacological treatments for insomnia: a protocol for a systematic review and network meta-analysis. Medicine (Baltimore) 2021, 100, Art. No: e26678. DOI: 10.1097/MD.0000000000026678 DOI: https://doi.org/10.1097/MD.0000000000026678
62. Rossman, J. Cognitive-behavioral therapy for insomnia: an effective and underutilized treatment for insomnia. Am. J. Lifestyle Med. 2019, 13, 544–547. DOI: 10.1177/1559827619867677 DOI: https://doi.org/10.1177/1559827619867677
63. Verbeek, I.H.; Konings, G.M.; Aldenkamp, A.P.; Declerck, A.C.; Klip, E.C. Cognitive behavioral treatment in clinically referred chronic insomniacs: group versus individual treatment. Behav. Sleep Med. 2006, 4, 135–151. DOI: 10.1207/s15402010bsm0403_1 DOI: https://doi.org/10.1207/s15402010bsm0403_1
64. Trauer, J.M.; Qian, M.Y.; Doyle, J.S.; Rajaratnam, S.M.; Cunnington, D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann. Intern. Med. 2015, 163, 191–204. DOI: 10.7326/M14-2841 DOI: https://doi.org/10.7326/M14-2841
65. Carney, C.E.; Edinger, J.D. Identifying critical beliefs about sleep in primary insomnia. Sleep 2006, 29, 342–350. DOI: 10.1093/sleep/29.3.342 DOI: https://doi.org/10.1093/sleep/29.3.342
66. Castronovo, V.; Galbiati, A.; Sforza, M.; Poletti, M.; Giarolli, L.; Kuo, T.; Zucconi, M.; Manconi, M.; Hensley, M.; Morin, C.; Ferini-Strambi, L. Long-term clinical effect of group cognitive behavioral therapy for insomnia: a case series study. Sleep Med. 2018, 47, 54–59. DOI: 10.1016/j.sleep.2018.03.017 DOI: https://doi.org/10.1016/j.sleep.2018.03.017
67. Soh, H.L.; Ho, R.C.; Ho, C.S.; Tam, W.W. Efficacy of digital cognitive behavioural therapy for insomnia: a meta-analysis of randomised controlled trials. Sleep Med. 2020, 75, 315–325. DOI: 10.1016/j.sleep.2020.08.020 DOI: https://doi.org/10.1016/j.sleep.2020.08.020
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jakub Starownik, Maciej Bara, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
